

REMARKS

Claims 1-95 were pending in the subject application. By this Amendment applicants have canceled claims 1-28 and 33-93 without prejudice or disclaimer, and added new claims 96-99. Accordingly, upon entry of this Amendment, claims 29-32 and 94-99 will be pending and under examination.

Applicants maintain that the amendments to the application do not raise any issue of new matter. Applicants have amended page 1 of the specification to update the continuing data for the subject application. Support for the additions to page 19 of the specification and for new claims 96-99 may be found inter alia in the specification, as originally-filed, on page 15, lines 20-28; page 19, lines 2-3; page 37, lines 30-31; and in Figure 4A. Support for the addition to page 29 may be found inter alia in the specification, as originally-filed, on page 22, lines 17-22, and page 29, lines 24-27. Applicants have replaced the original Sequence Listing with a new Sequence Listing which includes the sequences recited in new claim 96. Accordingly, applicants respectfully request that this Amendment be entered.

Applicants submit herewith as **Exhibit 3** a Sequence Listing in a computer readable form which complies with the requirement of 37 C.F.R. §1.824. In addition, applicants submit a Statement in Accordance with 37 C.F.R. §1.821(f), attached hereto as **Exhibit 2**, certifying that the computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. §1.821(e) contains the same information as the paper copy of the Sequence Listing attached hereto as **Exhibit 1**.

0959416 070301
FOED 20 97195950